Projects

DAPA-HF: Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

In this placebo-controlled trial, 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less weку randomly assigned to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes.

  1. N Engl J Med. 2019 September 19,  DOI: 10.1056/NEJMoa1911303

Back to the list